For the quarter ending 2025-09-30, ZIVO has $559,452 in assets. $3,846,055 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 57,222 | 9,823 | ||
| Accounts receivable | 0 | 34,364 | ||
| Prepaid expenses | 224,177 | 365,707 | ||
| Total current assets | 281,399 | 409,894 | ||
| Operating lease - right of use asset | 270,373 | 285,753 | ||
| Security deposit | 7,680 | 7,680 | ||
| Total assets | 559,452 | 703,327 | ||
| Accounts payable | 992,990 | 860,939 | ||
| Accounts payable - related party | 333,117 | - | ||
| Customer deposits | 15,000 | 34,364 | ||
| Current portion of long-term operating lease | 65,713 | 63,219 | ||
| Current portion of note payable | 139,223 | - | ||
| Accounts payable - related party | - | 70,056 | ||
| Convertible note - at fair value | 236,513 | 138,510 | ||
| Short term loan payable | 146,459 | 292,919 | ||
| Accrued interest | 71,313 | 65,628 | ||
| Accrued liabilities - employee bonus and salary | 1,613,940 | 1,433,953 | ||
| Long-term note payable, net of current portion | - | 46,962 | ||
| Total current liabilities | 3,614,268 | 2,959,588 | ||
| Lease liabilities | 220,124 | 237,523 | ||
| Long-term note payable, net of current portion | 11,663 | - | ||
| Total long-term liabilities | 231,787 | 284,485 | ||
| Total liabilities | 3,846,055 | 3,244,073 | ||
| Common stock, 0.001 par value, 25,000,000 shares authorized as of september 30, 2025 and december 31, 2024 3,832,327 and 3,621,335 issued and outstanding at september 30, 2025, and december 31, 2024, respectively | 3,832 | 3,817 | ||
| Additional paid-in capital | 140,560,590 | 140,273,406 | ||
| Accumulated deficit | -143,851,025 | -142,817,969 | ||
| Total stockholders' equity (deficit) | -3,286,603 | -2,540,746 | ||
| Total liabilities and stockholders' equity (deficit) | 559,452 | 703,327 | ||
Zivo Bioscience, Inc. (ZIVO)
Zivo Bioscience, Inc. (ZIVO)